Percutaneous annuloplasty (eg, intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, or intradiscal biacuplasty) for the treatment of chronic discogenic back pain is considered investigational.

Intraosseous radiofrequency nerve ablation of basivertebral nerve (e.g., INTRACEPT® Intraosseous Nerve Ablation System) is considered investigational.

POLICY GUIDELINES
None.

BENEFIT APPLICATION
None.

BLUECARD/NATIONAL ACCOUNT ISSUES
State or federal mandates (e.g., Federal Employee Program) may dictate that certain U.S. Food and Drug Administration–approved devices, drugs, or biologics may not be considered investigational, and thus these devices may be assessed only by their medical necessity.
MP 7.01.572
Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, and Biacuplasty

BACKGROUND

Discogenic Low Back Pain

Discogenic low back pain is a common, multifactorial pain syndrome that involves low back pain without radicular symptoms findings, in conjunction with radiologically confirmed degenerative disc disease.

Treatment

Typical treatment includes conservative therapy with physical therapy and medication management, with potential for surgical decompression in more severe cases.

A number of electrothermal intradiscal procedures have been introduced to treat discogenic low back pain; they rely on various probe designs to introduce radiofrequency (RF) energy into the disc. It has been proposed that heat-induced denaturation of collagen fibers in the annular lamellae may stabilize the disc and potentially seal annular fissures and that pain reduction may occur through the thermal coagulation of nociceptors in the outer annulus.

Some electrothermal intradiscal procedures are briefly described next.

With the intradiscal electrothermal annuloplasty procedure, a navigable catheter with an embedded thermal resistive coil is inserted posterolaterally into the disc annulus or nucleus. Using indirect RF energy, electrothermal heat is generated within the thermal resistive coil at a temperature of 90°C; the disc material is heated for up to 20 minutes. Proposed advantages of indirect electrothermal delivery of RF energy with intradiscal electrothermal annuloplasty include precise temperature feedback and control, and the ability to provide electrothermo-coagulation to a broader tissue segment than would be allowed with a direct RF needle.

Percutaneous intradiscal radiofrequency thermocoagulation uses direct application of RF energy. With percutaneous intradiscal radiofrequency thermocoagulation, the RF probe is placed into the center of the disc, and the device is activated for only 90 seconds at a temperature of 70°C. The procedure is not designed to coagulate, burn, or ablate tissue. The Radionics RF Disc Catheter System has been specifically designed for this purpose.

Intradiscal biacuplasty uses 2 cooled RF electrodes placed on the posterolateral sides of the intervertebral annulus fibrosus. It is believed that, by cooling the probes, a larger area may be treated than could occur with a regular needle probe.

Annuloplasty using a laser-assisted spinal endoscopy kit to coagulate the disc granulation tissue (percutaneous endoscopic laser annuloplasty) has also been described.

Regulatory Status

A variety of RF coagulation devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA), some of which are designed for disc nucleotomy. In 2002, the Oratec Nucleotomy Catheter (ORATEC Interventions, Menlo Park, CA, acquired by Smith & Nephew in 2002) was cleared for marketing by FDA through the 510(k) process. The predicate device was the SpineCATH® Intradiscal Catheter, which received FDA clearance for marketing in 1999. The Radionics (a division of Tyco Healthcare group) RF (Radiofrequency) Disc Catheter System received marketing clearance by FDA through the 510(k) process in 2000. FDA product code: GEI.

In 2005, the Baylis Pain Management Cooled Probe was also cleared for marketing by FDA through the 510(k) process. It is intended for use “in conjunction with the Radio Frequency Generator to create radiofrequency lesions in nervous tissue.” FDA product code: GXI.
Note: This evidence review does not address disc nucleoplasty, a technique based on the bipolar RF device (Coblation®; ArthroCare, Austin, TX, acquired by Smith & Nephew, 2014). With the coblation system, a bipolar RF device is used to provide lower energy treatment to the intervertebral disc, which is designed to provide tissue removal with minimal thermal damage to collateral tissue. Disc nucleoplasty is closer in concept to a laser discectomy in that tissue is removed or ablated to provide decompression of a bulging disc. Disc nucleoplasty and laser discectomy are considered in evidence review 7.01.93.

RATIONALE

This evidence review was created in December 1999 and has been updated regularly with searches of the MEDLINE database. The most recent literature update was performed through February 5, 2019. This review is based in part on TEC Assessments from 2002 and 2003. Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Clinical Context and Therapy Purpose

The purpose of intradiscal electrothermal procedures in patients who have discogenic back pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Do intradiscal electrothermal procedures improve the net health outcome in patients with discogenic back pain?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest is patients with discogenic back pain.

Interventions

The therapies being considered are intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, and intradiscal bicuplasty.

Comparators

The following therapies are currently being used to make decisions about intradiscal electrothermal procedures.
Relevant comparators are conservative management and surgical spinal decompression.

As with any therapy for pain, a placebo effect is anticipated, and thus randomized placebo-controlled trials are necessary to investigate the extent of the placebo effect and to determine whether any improvement with annuloplasty exceeds that associated with a placebo. Therefore, evidence reviewed for this review focuses on RCTs.

**Outcomes**

The general outcomes of interest are symptoms, functional outcomes, quality of life, and treatment-related morbidity.

**Intradiscal Electrothermal Procedures**

**Intradiscal Electrothermal Annuloplasty**

Pauza et al (2004) published the results of an RCT evaluating intradiscal electrothermal annuloplasty (IDEA; referred to as intradiscal electrothermal therapy in Pauza) in patients with discogenic low back pain, which was the focus of discussion in the 2003 TEC Assessment. The trial included 64 patients with low back pain of more than 6 months in duration who were randomized to IDEA or a sham procedure. Visual analog scale (VAS) scores for pain were reduced by an average of 2.4 cm in the IDEA group compared with 1.1 cm in the sham group, a statistically significant difference between groups (p=0.045). The mean change in the Oswestry Disability Index (ODI) score was also significantly greater for the IDEA group than for the sham group. Improvements in the 36-item Short-Form Health Survey (SF-36) bodily pain subscale score were slightly higher for the IDEA group. The trial also reported the percent change in VAS scores more than 2.0 cm, which is greater than the minimal clinically significant improvement of 1.8 to 1.9. When the VAS score was dichotomized in this way, a relative risk of 1.5 was observed with a 95% confidence interval of 0.82 to 2.74. While this single-center trial was well-designed with respect to randomization, clear description of the intervention, and use of valid and reliable outcomes measures, it does not permit conclusions about the relative effects of IDEA and placebo, and it is unclear whether IDEA achieves clinically and statistically significant improvements in measures of pain, disability, or quality of life.

In 2005, Freeman et al reported on an industry-sponsored, double-blinded, sham-controlled randomized trial evaluating IDEA (referred to as intradiscal electrothermal therapy in this report) in patients with chronic discogenic low back pain, marked functional disability, magnetic resonance imaging evidence of degenerative disc disease, and failure of conservative management. Both the active IDEA and sham groups had an intradiscal catheter that was navigated to cover at least 75% of the posterior annulus. Planned enrollment based on power analysis was for 75 patients; however, the trial was stopped early due to slower than expected recruitment after 57 patients (38 IDEA, 19 placebo) had been enrolled. Follow-up was for 6 months, and the outcome measure was successful treatment response, as defined by all of the following: (1) no neurologic deficit; (2) an increase on the Low Back Outcome Score of at least 7 points; and (3) improvements in the SF-36 physical functioning and bodily pain subscales scores of at least 1 standard deviation. No subject in either group achieved a successful treatment response. Outcomes were similar between the intradiscal electrothermal therapy and sham groups on the Low Back Outcome Score (38.31 vs 37.45), ODI score (39.77 vs 41.58), SF-36 subscale scores (35.10 vs 30.40), the Zung Depression Index score (41.39 vs 40.82), and the Modified Somatic Perception Questionnaire score (8.67 vs 8.6), respectively. None of the subgroup analyses showed statistically or clinically significant differences in study outcomes. No serious adverse events were reported in either group.

**Section Summary: Intradiscal Electrothermal Annuloplasty**
Two RCTs on IDEA have reported conflicting results, with one finding a benefit for IDEA and the other no benefit. The most recent RCT identified was from 2005. No recent literature on IDEA has been identified.

**Percutaneous Intradiscal Radiofrequency Annuloplasty**

There is relatively little published data on percutaneous intradiscal radiofrequency thermocoagulation (PIRFT). In 2001, Barendse et al reported on a double-blind trial that randomized 28 patients with chronic low back pain to PIRFT or a sham-control group. The primary outcome was the percentage of success at 8 weeks, as measured by changes in pain level, impairment, ODI scores, and analgesics taken. At the end of 8 weeks, there were 2 treatment successes in the sham group and one in the treatment group. Trialists concluded that PIRFT was no better than placebo in reducing pain and disability.

In 2009, Kvarstein et al published 12-month follow-up from an RCT of intrannular radiofrequency thermal disc therapy using the discTRODE probe. Recruitment was discontinued when blinded interim analysis of the first 20 patients showed no trend toward overall effect or difference in pain intensity between active and sham treatment at 6 months. At 12 months, there was a reduction from baseline pain but no significant difference between the groups. Two patients from each group reported an increase in pain.

**Section Summary: Percutaneous Intradiscal Radiofrequency Annuloplasty**

Two sham-controlled randomized trials showed no evidence of a benefit with PIRFT. One study found that only 1 of 14 patients was considered a treatment success. The other was terminated after blinded interim analysis showed no trend to benefit compared with sham.

**Intradiscal Radiofrequency Biacuplasty**

Kapural, Desai, and colleagues have published several studies on the use of transdiscal radiofrequency annuloplasty using 2 transdiscal probes (biacuplasty) in patients with discogenic lower back pain, including a 2013 industry-sponsored, phase 1, double-blind RCT and a 2016 RCT. In the phase 1 RCT by Kapural et al (2013), of 1894 patients screened, 1771 (94%) did not meet inclusion criteria. Sixty-four subjects consented and were enrolled. Outcome measures were the SF-36 physical functioning subscale (0-100), a numeric rating scale (NRS) for pain (0-10), and the ODI (0-100). There were no significant differences between the groups at 1 month or 3 months. At 6 months, the biacuplasty group showed a significantly greater change from baseline for the SF-36 (15.0 vs 2.63), NRS (-2.19 vs -0.64), and ODI (-7.43 vs 0.53) scores. Mean SF-36 and NRS scores were considered to be clinically significant, but mean ODI scores did not achieve the minimally important difference of 10 points. With clinical success defined post hoc as a 15-point increase in physical function together with a greater than 2-point decrease in pain, 30% of biacuplasty patients and 3% of sham-treated patients were considered successful. There was no significant difference in opioid use between groups.

In 2015, Kapural et al reported on the unblinded 12-month follow-up from this phase 1 trial. Improvements continued through 12 months, with a change from baseline to posttreatment of 47.0 to 68.9 (of 100) on the SF-36 physical functioning subscale (p<0.01) and 7.1 to 4.4 (of 10) on the NRS (p<0.01). Although the change in NRS score was statistically significant, the magnitude of the decrease was modest, and a final NRS score (4.4) remained high. The change in ODI score (from 40.37 at baseline to 32.44 at 12 months) was also modest (p=0.05). Opioid usage did not decrease significantly (53.47 mg at baseline to 34.07 mg at follow-up, p=0.23).

In the 2016 RCT by Desai et al, 63 patients with lumbar discogenic pain diagnosed by provocation discography were randomized to intradiscal biacuplasty plus conservative medical management (n=29) or medical management alone (n=34). Another 234 patients were scheduled for diagnostic discography.
but did not meet inclusion criteria. The primary outcome (the mean reduction in VAS score for pain at 6 months) was significantly greater in the biacuplasty group (-2.4) than in the medical management group (-0.56; p=0.02). The secondary outcomes were not statistically significant, which included the proportion of responders, defined as a 2-point or 30% decrease in VAS scores, which was achieved in 50% of the biacuplasty group compared to 18% of controls (p=0.073). Investigators did not report whether the trial was adequately powered. Other limitations of this industry-sponsored trial were the lack of a sham-control and patient blinding, which could contribute to a placebo effect in the subjective pain outcomes.

Of the 29 patients originally randomized to intradiscal biacuplasty, 22 (76%) were available for 12-month follow-up. Mean 12-month change in VAS score was -2.2 (from 6.7 at baseline to 4.4 at 12 months, p=0.001). After 6 months, patients randomized to medical management were allowed to receive intradiscal biacuplasty and were followed for another 6 months; 25 of 34 patients crossed over. VAS score improved from 7.0 to 4.7 (p<0.001) in the crossover group, and 55% were considered to be responders.

**Section Summary: Intradiscal Radiofrequency Biacuplasty**

Two industry-sponsored RCTs have assessed use of biacuplasty to treat chronic low back pain. In one, only 6% of subjects screened met the strict inclusion and exclusion criteria for the study. Significant differences in outcomes were observed at 6 months, but not at 1 month or 3 months, and the definition of successful treatment appears to have been post hoc. In the second multicenter RCT, 63 patients met inclusion criteria, which included a positive result on provocation discography. There was a significant treatment effect for the primary outcome measure, but not the secondary outcome measures. This trial was not sham-controlled, and it was not reported whether it was adequately powered. Additional sham-controlled trials in a broader population of patients are needed to determine the effect of this treatment with greater certainty.

**Summary of Evidence**

For individuals who have discogenic back pain who receive intradiscal thermal annuloplasty, radiofrequency annuloplasty, or biacuplasty, the evidence includes a small number of randomized controlled trials. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two RCTs on intradiscal electrothermal annuloplasty have reported conflicting results, with one reporting benefit for intradiscal electrothermal annuloplasty and the other reporting no benefit. There is a lack of evidence to support a role for radiofrequency annuloplasty with either a single or a double (biacuplasty) probe. One sham-controlled randomized controlled trials assessing biacuplasty has suggested that this procedure may provide modest benefit to highly select patients; confirmation of these results in a broader population is needed. Further study in a sham-controlled trial with a representative population of patients is needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Intraosseous Radiofrequency Nerve Ablation**: Radiofrequency ablation of intraosseous nerves is an emerging technology intended for treatment of chronic low back pain. Intraosseous nerves are reportedly found within the vertebrae, are referred to as basivertebral nerves and are present in the basivertebral foramen. Authors contend the nerves may be a source of intraosseous back pain and that interruption of the nerve pathway using radiofrequency will relieve the associated pain. One device under investigation, The INTERCEPT® System (Relievant MedSystems, Inc, Redwood City, CA) recently received FDA approval for use as a minimally invasive radiofrequency system for treatment of chronic
lumbar back pain at one or more levels (i.e., L3 to S1), when back pain is present despite at least six months of conservative care and is accompanied by either Type I or Type 2 Modic changes on MRI (FDA K153272). Evidence in the peer reviewed, published scientific literature evaluating ablation of basivertebreal nerves consists mainly of pilot studies and is insufficient to support safety and efficacy at this time; additional studies are needed to support strong evidence-based conclusions.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

American Society of Interventional Pain Physicians
A 2013 review of the evidence informing American Society of Interventional Pain Physicians guidelines found limited-to-fair evidence for intradiscal electrothermal therapy (IDET; another term for intradiscal electrothermal annuloplasty) and biacuplasty and limited evidence for percutaneous intradiscal radiofrequency thermocoagulation (PIRFT). These guidelines updated 2007 guidelines, which concluded that the evidence was moderate for management of chronic discogenic low back pain with IDET. Complications included catheter breakage, nerve root injuries, post-IDET disc herniation, cauda equina syndrome, infection, epidural abscess, and spinal cord damage. The evidence for PIRFT was limited, with complications similar to IDET.

National Institute for Health and Care Excellence
A National Institute for Health and Care Excellence (NICE) guidance, updated in 2016, indicated that the evidence on safety and efficacy of PIRFT for low back pain was “limited” and should only be used by “special arrangement”.

The NICE guidance on electrothermal annuloplasty was also updated in 2016. NICE considered evidence on the efficacy of PIRFT for low back pain to be inconsistent and of poor quality, although no major safety concerns were identified. NICE recommended PIRFT only with special arrangements for clinical governance, consent, and audit or research.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
The Centers for Medicare & Medicaid Services has determined that thermal intradiscal procedures (TIPs), including IDET and PIRFT, “are not reasonable and necessary for the treatment of low back pain. Therefore, TIPs, which include procedures that employ the use of a radiofrequency energy source or electrothermal energy to apply or create heat and/or disruption within the disc for the treatment of low back pain, are noncovered.”

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in March 2019 did not identify any ongoing or unpublished trials that would likely influence this review.

ESSENTIAL HEALTH BENEFITS
The Affordable Care Act (ACA) requires fully insured non-grandfathered individual and small group benefit plans to provide coverage for ten categories of Essential Health Benefits (“EHBs”), whether the benefit plans are offered through an Exchange or not. States can define EHBs for their respective state.
States vary on how they define the term small group. In Idaho, a small group employer is defined as an employer with at least two but no more than fifty eligible employees on the first day of the plan or contract year, the majority of whom are employed in Idaho. Large group employers, whether they are self-funded or fully insured, are not required to offer EHBs, but may voluntary offer them.

The Affordable Care Act requires any benefit plan offering EHBs to remove all dollar limits for EHBs.

REFERENCES

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Intradiscal electrothermal therapy for chronic low back pain. TEC Assessments Apr 2002;Volume 17:Tab 11. PMID 11010675

**CODES**

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>22526</td>
<td>Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level</td>
</tr>
<tr>
<td></td>
<td>22527</td>
<td>Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td></td>
<td>72285</td>
<td>Discography, cervical or thoracic, radiological supervision and interpretation</td>
</tr>
<tr>
<td></td>
<td>72295</td>
<td>Discography, lumbar, radiological supervision and interpretation</td>
</tr>
<tr>
<td></td>
<td>62290</td>
<td>Injection procedure for discography, each level; lumbar</td>
</tr>
<tr>
<td></td>
<td>62291</td>
<td>Injection procedure for discography, each level; cervical or thoracic</td>
</tr>
<tr>
<td></td>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C9752</td>
<td>Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum</td>
</tr>
<tr>
<td></td>
<td>C9753</td>
<td>Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>ICD-10-CM</td>
<td>0R530ZZ, 0R550ZZ, 0R590ZZ, 0R5B0ZZ</td>
<td>ICD-10-CM codes are only used for inpatient services.</td>
</tr>
<tr>
<td>ICD-10-PCS</td>
<td>0S520ZZ, 0S540ZZ</td>
<td>Destruction, upper joints, open, cervical and thoracic disc code list</td>
</tr>
<tr>
<td>Type of Service</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>Place of Service</td>
<td>Outpatient/Inpatient</td>
<td></td>
</tr>
</tbody>
</table>

**POLICY HISTORY**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>Action</td>
<td>Details</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>07/10/14</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 3, 2014; policy statement unchanged</td>
</tr>
<tr>
<td>07/09/15</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 10, 2015; reference 17 added. Policy statement unchanged</td>
</tr>
<tr>
<td>09/01/16</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho annual review, no change to policy.</td>
</tr>
<tr>
<td>01/27/17</td>
<td>Replace policy</td>
<td>Policy updated with literature review through November 1, 2016; references 9-10 added; reference 14 updated; some references removed. Title changed to “Percutaneous intradiscal electrothermal annuloplasty, radiofrequency annuloplasty, and biacuplasty.” Policy statement terminology revised to reflect the changes in the title but the intent is unchanged.</td>
</tr>
<tr>
<td>01/30/18</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted. Policy updated with literature review through November 21, 2017; no references added; note 13 updated. Policy statement unchanged.</td>
</tr>
<tr>
<td>01/24/19</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted, effective 01/24/2019. Policy updated with literature review through November 21, 2017; no references added; note 13 updated. Policy statement unchanged.</td>
</tr>
<tr>
<td>04/18/19</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted, effective 04/18/2019. Policy updated with literature review through February 5, 2019; no references added. Policy statement unchanged.</td>
</tr>
<tr>
<td>08/22/19</td>
<td>Replace policy</td>
<td>Policy number updated from 7.01.72 to 7.01.572. Blue Cross of Idaho adopted change as noted, effective 11/20/2019. Additional policy statement added “Intraosseous radiofrequency nerve ablation of basivertebral nerve (e.g., INTRACEPT® Intraosseous Nerve Ablation System) is investigational”.</td>
</tr>
</tbody>
</table>